GJA1: Gap Junction Protein and Potential Drug Target (G2697)

Target Name: GJA1

NCBI ID: G2697

GJA1

GJA1: Gap Junction Protein and Potential Drug Target

GJA1 (gap junction protein, alpha 1, 43kDa) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and liver. It is a member of the gap junction protein family, which are proteins that help to facilitate communication between cells at the surface of the body.

GJA1 is a 43kDa protein that is made up of 115 amino acid residues. It has a characteristic 伪-helical structure, with a clear N-terminal and C-terminal region, and a middle region that is composed of multiple 尾-strands. The 尾-strands are held together by hydrogen bonds and form a repeating pattern that gives the protein its characteristic 伪-helical shape.

GJA1 is involved in a number of different processes in the body, including the regulation of ion and solute transport, and the maintenance of cell structure and integrity. It is also involved in the development and progression of a number of diseases, including cancer.

One of the key functions of GJA1 is its role in the formation of gap junctions, which are specialized junctions that form between cells and are involved in the transfer of electrical and signaling signals. GJA1 helps to regulate the formation and stability of these gap junctions, which are critical for the proper functioning of many different tissues in the body.

In addition to its role in gap junction formation, GJA1 is also involved in the regulation of a variety of intracellular signaling pathways. It has been shown to play a role in a number of signaling pathways that are involved in cell growth, differentiation, and survival.

GJA1 is also of interest as a potential drug target. Its involvement in a number of different signaling pathways makes it a potential target for a variety of drugs that are used to treat a wide range of diseases. For example, GJA1 has been shown to be involved in the development and progression of cancer, and may be a useful target for drugs that are used to treat this disease.

In addition to its potential as a drug target, GJA1 is also of interest as a biomarker. Its expression has been shown to be regulated in a variety of tissues and conditions, and may be a useful indicator of disease status or the response to therapeutic treatment.

Overall, GJA1 is a complex protein that is involved in a number of different processes in the body. Its role in gap junction formation and intracellular signaling pathways makes it a potential target for a variety of drugs, and its potential as a biomarker makes it an important molecule to study in order to better understand the mechanisms of disease.

Protein Name: Gap Junction Protein Alpha 1

Functions: Gap junction protein that acts as a regulator of bladder capacity. A gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. May play a critical role in the physiology of hearing by participating in the recycling of potassium to the cochlear endolymph. Negative regulator of bladder functional capacity: acts by enhancing intercellular electrical and chemical transmission, thus sensitizing bladder muscles to cholinergic neural stimuli and causing them to contract (By similarity). May play a role in cell growth inhibition through the regulation of NOV expression and localization. Plays an essential role in gap junction communication in the ventricles (By similarity)

The "GJA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GJA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets